中华老年心脑血管病杂志

[1]Bergmark BA, Mathenge N, Merlini PA, et al. Acute coronary syndromes[J]. Lancet, 2022, 399(10332):1347-1358. DOI:10.1016/S0140-6736(21)02391-6.

[2]Zaman S, Wasfy JH, Kapil V, et al. The Lancet Commission on rethinking coronary artery disease:moving from ischaemia to atheroma[J]. Lancet, 2025, 405(10486):1264-1312. DOI:10.1016/S0140-6736(25)00055-8.

[3]Liu MB, He XY, Yang XH, et al. Interpretation of annual report on cardiovascular health and diseases in China 2024[J]. Biomed Environ Sci, 2025, 38(8):893-917. DOI:10.3967/bes2025.099.

[4]Reynolds HR, Smilowitz NR. Ischaemia with non-obstructive coronary arteries in the 2024 European Society of Cardiology guidelines for the management of chronic coronary syndromes[J].Eur Heart J Acute Cardiovasc Care, 2025, 14(3):173-177. DOI:10.1093/ehjacc/zuaf005.

[5]Kraler S, Mueller C, Libby P, et al. Acute coronary syndromes:mechanisms, challenges, and new opportunities[J]. Eur Heart J, 2025,46(29):2866-2889. DOI:10.1093/eurheartj/ehaf289.

[6]Boden WE, De Caterina R, Kaski JC, et al. Myocardial ischemic syndromes:a new nomenclature to harmonize evolving international clinical practice guidelines[J]. Circulation, 2024, 150(20):1631-1637. DOI:10.1161/CIRCULATIONAHA.123.065656.

[7]Braunwald E.Will primordial prevention change cardiology?[J]. Eur Heart J, 2023, 44(35):3307-3308. DOI:10.1093/eurheartj/ehad459.

[8]Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s essential8:updating and enhancing the american heart association's construct of cardiovascular health:a presidential advisory from the American Heart Association[J]. Circulation, 2022, 146(5):e18-e43. DOI:10.1161/CIR.0000000000001078.

[9]Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes:a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation, 2025, 151(13):e771-e862. DOI:10.1161/CIR.0000000000001309.

[10]Reddy RK, Koeckerling D, Eichhorn C, et al. Early invasive or conservative strategies for older patients with acute coronary syndromes:a meta-analysis[J]. JAMA Intern Med, 2025, 185(8):966-975. DOI:10.1001/jamainternmed.2025.2058.

[11]Landi A, Gorog DA, Valgimigli M.Swinging pendulum between risks and benefits of antiplatelet agents:a call for consistency in the interpretation of evidence and guideline recommendations[J].Circulation, 2025, 151(2):126-128. DOI:10.1161/CIRCULATIONAHA.124.070797.

[12]Gao C, Zhu B, Ouyang F, et al. Stepwise dual antiplatelet therapy deescalation in patients after drug coated balloon angioplasty(RECCAGEFREEⅡ):multicentre, randomised, open label, assessor blind,non-inferiority trial[J]. BMJ, 2025, 388:e082945. DOI:10.1136/bmj-2024-082945.

[13]Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias[J]. Atherosclerosis, 2025, 409:120479. DOI:10.1016/j.atherosclerosis.2025.120479.

[14]Sinha SS, Morrow DA, Kapur NK, et al. 2025 concise clinical guidance:an acc expert consensus statement on the evaluation and management of cardiogenic shock:a report of the American College of Cardiology Solution Set Oversight Committee[J]. J Am Coll Cardiol, 2025, 85(16):1618-1641. DOI:10.1016/j.jacc.2025.02.018.

[15]Butler J, Hammonds K, Talha KM, et al. Incident heart failure and recurrent coronary events following acute myocardial infarction[J].Eur Heart J, 2025, 46(16):1540-1550. DOI:10.1093/eurheartj/ehae885.

[16]Paoli G, Notarangelo MF, Mattioli M, et al. ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial:a multicenter fully nurse-coordinated intensive intervention program[J].Am Heart J, 2018, 203:12-16. DOI:10.1016/j.ahj.2018.06.001.

[17]McLachlan A, Kerr A, Lee M. A nurse-led and medically supported outpatient follow-up model following an acute coronary syndrome is as safe and effective as medical follow-up alone(ANZACS-QI 69)[J].N Z Med J, 2022, 135(1563):12-28. DOI:10.26635/6965.5787.